间歇性质子抑制剂治疗低风险的非性上胃肠道出血可能显著节省成本
Yang Lei1, Jennifer Halasz1, Kerri L Novak1
1Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4Z6, Canada.
切换低风险的非变形上胃肠道出血患者从连续到间歇性质子抑制剂 (PPI) 治疗可以每年节省数百万. 这种方法为医疗保健系统提供了显著的成本节约.
科学领域:
- 胃肠病学 胃肠病学
- 卫生经济学 卫生经济学
- 临床药房 临床药房
背景情况:
- 高剂量质子抑制剂 (PPI) 疗法对非的上部胃肠道出血 (NV-UGIB) 有效.
- 在低风险NV-UGIB患者中,间歇性PPI使用可能更具成本效益.
- 目前的做法可能涉及在低风险人群中过度使用连续IVPPI.
研究的目的:
- 通过将低风险NV-UGIB患者转换为间歇性PPI治疗来估计潜在的年度成本节约.
- 分析NV-UGIB中不同PPI管理策略的经济影响.
主要方法:
- 在阿尔伯塔省卡尔加里的4141名NV-UGIB患者的回顾性分析 (2015年7月至2017年3月).
- 根据病变风险分层的患者 (没有内镜,高风险,低风险) 和PPI疗法 (没有,口服,间歇性IV,连续IV).
- 每个子组的计算平均逗留时间 (LOS) 和相关成本.
主要成果:
- 连续IVPPI的低风险患者的平均LOS为6.8天,而间歇性IVPPI的4.9天.
- 将连续IVPPI患者切换为间歇性IVPPI可以每年节省3852个患者日.
- 据估计,如果在这个队列中用间歇性IV PPI取代连续IV PPI,每年可节省11,714,390加元 (2017加元).
结论:
- 现实数据表明,通过优化低风险NV-UGIB患者的PPI治疗,可以实现显著的成本节约.
- 在低风险NV-UGIB患者中,从连续IV PPI过渡到间歇性IV PPI是降低成本的可行策略.
- 这项研究强调了基于患者风险分层的定制PPI疗法的经济益处.
更多相关视频
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
05:50Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
Published on: September 22, 2023
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
